EcoDrugPlus

Voltage-Dependent P/q-Type Calcium Channel Subunit Alpha-1a-Like

Ensembl ID : ENSSLDG00000018378
Gene Symbol: LOC111665625
3 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSSLDG00000023153
Gene Symbol: LOC111663254
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSSLDG00000025498
Gene Symbol: LOC111645842
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSSLDG00000014509
Gene Symbol: LOC111661173
3 Cross references
167 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSSLDG00000014534
Gene Symbol: LOC111661188
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSSLDG00000014490
Gene Symbol: LOC111661224
4 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSSLDG00000023835
Gene Symbol: LOC111671920
3 Cross references
226 Possible Orthologues:

Wee1-Like Protein Kinase 1-A

Ensembl ID : ENSSLDG00000001684
Gene Symbol: LOC111654312
4 Cross references
203 Possible Orthologues:

Wee1-Like Protein Kinase 1-A

Ensembl ID : ENSSLDG00000006870
Gene Symbol: LOC111647704
3 Cross references
203 Possible Orthologues:

Wee1-Like Protein Kinase 1-A

Ensembl ID : ENSSLDG00000005297
Gene Symbol: LOC111646661
4 Cross references
203 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSSLDG00000015215
Gene Symbol: XDH
3 Cross references
208 Possible Orthologues:

Ensembl ID : ENSSLDG00000024227
Gene Symbol: -
Cross references: -
161 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).